Postmenopausal women with breast cancer who successfully complete 5years of tamoxifen therapy derive significant benefit from anadditional 3 years of therapy with the anastrozole, an aromataseinhibitor, according to study findings published in the Journal ofthe National Cancer Institute.
More...